[{"quiz_id": "ABMS20260101_kimi-k2-thinking_p02", "question_id": "ABMS20260101_kimi-k2-thinking_p02-001", "question": "A 35-year-old man develops DRESS syndrome 3 weeks after starting phenytoin. He has fever, eosinophilia, atypical lymphocytosis, and transaminitis (AST 450 U/L). HHV-6 PCR becomes positive at day 16 of illness. What is the clinical significance of this virologic finding?", "options": ["Confirms phenytoin as the causative drug", "Indicates need for ganciclovir antiviral therapy", "Predicts higher risk of disease flare and organ damage", "Represents asymptomatic viral reactivation without prognostic value", "Suggests alternative diagnosis of acute HHV-6 infection"], "answer": "C", "answer_index": 2, "explanation": "HHV-6 reactivation at weeks 2-3 in DRESS is pathogenically linked to disease severity, predicting higher risk of relapse, end-organ damage, and prolonged course. It indicates need for more aggressive immunosuppression, not antiviral therapy, as the virus is a marker of immune dysregulation.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Dermatology", "abms_specialty": "Dermatology", "abms_source": "topics_mapped", "source_label_raw": "Dermatology", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-010", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed126", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed126.jsonl", "pred": "C", "model_outputs": "Rationale:\nThe patient presents with DRESS syndrome, a severe drug hypersensitivity reaction, triggered by phenytoin. The diagnosis of DRESS is supported by the presence of fever, eosinophilia, atypical lymphocytosis, and transaminitis, occurring after starting a causative drug.\n\nHuman herpesvirus 6 (HHV-6) reactivation is a known complication of DRESS syndrome. While HHV-6 is a common virus, its reactivation during DRESS is not merely coincidental; it is often associated with more severe disease course and complications. Studies have demonstrated that HHV-6 reactivation in DRESS can contribute to ongoing inflammation, immune dysregulation, and consequently, an increased risk of disease flare and further organ damage (e.g., hepatic, renal, or hematologic involvement).\n\nLet's evaluate the options:\nA. Confirms phenytoin as the causative drug: The diagnosis of DRESS is based on the clinical presentation, history of drug exposure, and exclusion of other causes. HHV-6 reactivation does not confirm the causative drug.\nB. Indicates need for ganciclovir antiviral therapy: Ganciclovir is not routinely indicated for HHV-6 reactivation in the context of DRESS unless there is severe, proven widespread disease or significant immunocompromise. The significance here is not treatment indication.\nC. Predicts higher risk of disease flare and organ damage: This aligns with current understanding. HHV-6 reactivation is a marker for more severe DRESS and potential complications.\nD. Represents asymptomatic viral reactivation without prognostic value: While HHV-6 can be reactivated asymptomatically in some settings, in the context of DRESS, it has clinical implications and prognostic value, indicating a potentially more severe course.\nE. Suggests alternative diagnosis of acute HHV-6 infection: The patient has a clear drug-induced DRESS syndrome. The HHV-6 finding occurring during the illness is more indicative of reactivation secondary to the severe inflammatory state of DRESS, rather than an acute primary infection being the sole cause or an alternative diagnosis that explains the DRESS.\n\nTherefore, the most accurate clinical significance of a positive HHV-6 PCR in this scenario is its association with a worse prognosis and increased risk of complications.\n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p02", "question_id": "ABMS20260101_kimi-k2-thinking_p02-002", "question": "A 58-year-old kidney transplant recipient (deceased donor, 8 months post-transplant) presents with rising creatinine from 1.2 to 2.1 mg/dL. Plasma BK virus PCR is 18,000 copies/mL. Allograft biopsy shows Banff class B BK virus nephropathy. Current immunosuppression: tacrolimus 5 mg twice daily (trough 8 ng/mL), mycophenolate mofetil 1000 mg twice daily, prednisone 5 mg daily. What is the first immunosuppression modification?", "options": ["Reduce tacrolimus dose by 50%", "Reduce mycophenolate mofetil by 50%", "Discontinue tacrolimus and switch to cyclosporine", "Discontinue mycophenolate mofetil completely", "Reduce prednisone to 2.5 mg daily"], "answer": "B", "answer_index": 1, "explanation": "For BK viremia >10,000 copies/mL with Banff class B nephropathy, first-line therapy is mycophenolate dose reduction by 50% or complete discontinuation. Tacrolimus reduction is second-line if viremia persists after 2-4 weeks. This sequence preserves tacrolimus (the cornerstone immunosuppressant) while reducing the antiproliferative agent that most impairs viral clearance. Steroids should not be reduced initially.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Urology", "abms_specialty": "Urology", "abms_source": "target_topic", "source_label_raw": "Urology", "source_quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "source_question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-005", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251225T234023630Z_kimi-k2-thinking_seed133", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251225T234023630Z_kimi-k2-thinking_seed133.jsonl", "pred": "D", "model_outputs": "NOT FOR CLINICAL USE.\nThe question asks for the first immunosuppression modification for a kidney transplant recipient with BK virus nephropathy. Treatment of BK virus nephropathy primarily involves reducing immunosuppressive therapy. Common strategies include reducing the dose of calcineurin inhibitors (CNIs) like tacrolimus or discontinuing antiproliferative agents like mycophenolate mofetil (MMF).\n\nLet's analyze the options:\nA. Reduce tacrolimus dose by 50%: With a current trough of 8 ng/mL, a 50% reduction would bring the trough to approximately 4 ng/mL. While CNI reduction is essential, a trough of 4 ng/mL may be considered very low and could significantly increase the risk of acute cellular rejection, especially 8 months post-transplant. Some protocols suggest CNI reduction by 25-50%, but the specific current trough level is important.\n\nB. Reduce mycophenolate mofetil by 50%: Reducing MMF from 1000 mg twice daily to 500 mg twice daily is a significant reduction in immunosuppression, but it may not be sufficient to control BK virus replication and nephropathy.\n\nC. Discontinue tacrolimus and switch to cyclosporine: Switching between CNIs is generally not the first-line treatment for BK virus nephropathy; reduction of the current CNI or discontinuation of MMF is usually preferred.\n\nD. Discontinue mycophenolate mofetil completely: Discontinuing MMF provides a substantial reduction in overall immunosuppression. This is a well-established and commonly employed first-line strategy for managing BK virus nephropathy. It significantly decreases the burden of immunosuppression without immediately pushing the CNI level into a potentially rejection-risk zone.\n\nE. Reduce prednisone to 2.5 mg daily: Prednisone is usually maintained at a low dose (like 5 mg daily) in stable transplant recipients and is not typically reduced further as a first step for BK virus nephropathy. Its reduction is more often considered for managing side effects or in specific immune rebound scenarios.\n\nConsidering the options and common practice guidelines for BK virus nephropathy, discontinuing mycophenolate mofetil completely is a frequently utilized and effective initial step. It offers a robust reduction in immunosuppression that can allow the immune system to gain control over the viral infection. While reducing tacrolimus is also crucial, a 50% reduction from a trough of 8 ng/mL to 4 ng/mL might pose an unacceptably high risk of rejection as the *first* modification in many clinical scenarios compared to discontinuing MMF.\n\nThe final answer is $\\boxed{D}$."}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p02", "question_id": "ABMS20260101_kimi-k2-thinking_p02-003", "question": "A 55-year-old man has left vocal fold paralysis 6 months after thyroidectomy, with persistent aspiration and breathy voice. EMG shows absent motor unit potentials. What is the optimal injection laryngoplasty material?", "options": ["A) Hyaluronic acid gel for temporary medialization", "B) Calcium hydroxylapatite paste for permanent augmentation", "C) Autologous fat injection for long-term volume restoration", "D) Gelfoam paste for temporary 3-month effect", "E) Polydimethylsiloxane for permanent irreversible medialization"], "answer": "B", "answer_index": 1, "explanation": "For permanent vocal fold paralysis with absent EMG potentials, calcium hydroxylapatite provides durable medialization without migration. Its high viscosity prevents particle dispersion, and it integrates into tissue without foreign body reaction. Hyaluronic acid and Gelfoam are temporary (<6 months) and unsuitable for permanent paralysis. Autologous fat has unpredictable resorption (50-80% at 1 year), and polydimethylsiloxane risks granuloma formation and airway compromise if overinjected.", "generator_model": "kimi-k2-thinking", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Otolaryngology", "abms_specialty": "Otolaryngology", "abms_source": "target_topic", "source_label_raw": "Otolaryngology", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed130", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed130-016", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed130.jsonl", "pred": "E", "model_outputs": "The patient has left vocal fold paralysis 6 months after thyroidectomy, with persistent aspiration and a breathy voice. EMG showing absent motor unit potentials strongly suggests irreversible damage to the recurrent laryngeal nerve. The goal of treatment is to medialize the paralyzed vocal fold to improve voice and prevent aspiration. Injection laryngoplasty is a less invasive option for this purpose.\n\nLet's analyze the materials:\n\nA. Hyaluronic acid gel: This is a temporary bio-implant. Its duration of effect is typically 6-12 months. Given the likely permanent paralysis, a temporary solution would not be optimal.\n\nB. Calcium hydroxylapatite paste: This is a semi-permanent bio-implant. It can provide bulk for 12-18 months or longer. While a good option for long-term medialization, it is not technically permanent.\n\nC. Autologous fat injection: This is a method for long-term volume restoration, but the survival and longevity of fat grafts can be variable, often requiring repeat injections. It is considered a long-term solution, but its predictability can be less than permanent implants.\n\nD. Gelfoam paste: This is a temporary, resorbable implant material that typically lasts only a few months (e.g., 3-6 months). It is not suitable for treating persistent paralysis.\n\nE. Polydimethylsiloxane (PDMS): This is a silicone-based material, often referred to as Silastic or similar formulations, used for permanent vocal fold medialization when injected. It provides stable, permanent bulk to reconstruct the vocal fold margin. For a confirmed permanent vocal fold paralysis demonstrated by absent motor unit potentials on EMG, a permanent implant material is generally considered the optimal choice to achieve lasting functional improvement.\n\nGiven the likely permanent nature of the nerve injury and persistent severe symptoms, a permanent solution is typically preferred for optimal and long-lasting results. Among the options provided, Polydimethylsiloxane is the material designed for permanent irreversible medialization.\n\nThe answer is (E)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p02", "question_id": "ABMS20260101_kimi-k2-thinking_p02-004", "question": "A 45-year-old man with T6 complete spinal cord injury has a stage 4 sacral pressure ulcer with positive probe-to-bone test and MRI showing marrow edema limited to cortex. He has been on antibiotics for 4 weeks with minimal improvement. What is definitive management?", "options": ["A) Continue suppressive antibiotics indefinitely with wound care", "B) Surgical debridement to bone with burr drilling, VAC therapy, then gluteal myocutaneous flap", "C) Radical debridement with partial sacrectomy and omental flap", "D) Transcutaneous bone biopsy and targeted IV antibiotics for 12 weeks", "E) Osteomyelitis excision with free latissimus dorsi muscle flap"], "answer": "B", "answer_index": 1, "explanation": "Stage 4 sacral ulcer with cortical osteomyelitis requires surgical debridement with burr drilling of exposed bone to bleeding cortex, followed by VAC therapy to prepare granulation tissue, then gluteal myocutaneous flap coverage. This achieves 85% healing rates. Partial sacrectomy is reserved for medullary involvement. Suppressive antibiotics alone fail in 70% of cases, and free flaps are unnecessary when local muscle is available and viable.", "generator_model": "kimi-k2-thinking", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Physical Medicine and Rehabilitation", "abms_specialty": "Physical Medicine and Rehabilitation", "abms_source": "target_topic", "source_label_raw": "Physical Medicine and Rehabilitation", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed130", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed130-017", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed130.jsonl", "pred": "B", "model_outputs": "The patient presents with a stage 4 sacral pressure ulcer, positive probe-to-bone test, and MRI findings indicative of early osteomyelitis (marrow edema limited to cortex). The lack of improvement after 4 weeks of antibiotics suggests that conservative management is insufficient and surgical intervention is required.\n\n*   Option A is incorrect because suppressive antibiotics are not definitive management for osteomyelitis and a non-healing stage 4 ulcer.\n*   Option B describes a comprehensive surgical approach:\n    *   Surgical debridement to bone: Essential to remove all necrotic tissue and potentially involved bone.\n    *   Burr drilling: Can facilitate drainage and revascularization of the bone in cases of early osteomyelitis with cortical involvement.\n    *   VAC therapy: A well-established adjunct for managing complex wounds, promoting granulation tissue and preparing the wound bed.\n    *   Gluteal myocutaneous flap: An appropriate reconstructive option for covering large sacral defects, providing well-vascularized tissue.\n*   Option C suggests radical debridement with partial sacrectomy. While debridement is necessary, sacrectomy might be excessive if the osteomyelitis is limited to the cortex, and an omental flap is less commonly used for sacral reconstruction compared to local flaps.\n*   Option D proposes biopsy and antibiotics, but this does not address the debridement of necrotic tissue and infected bone, which is crucial for healing.\n*   Option E suggests osteomyelitis excision with a free latissimus dorsi flap. While excision of infected bone is correct, a free flap is a more complex reconstruction usually reserved for larger or more challenging defects where local or regional flaps are not viable. A gluteal flap is typically preferred for sacral defects.\n\nOption B provides the most appropriate combination of debridement, wound management, and reconstruction for a stage 4 sacral pressure ulcer with evidence of osteomyelitis that has failed conservative management.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p02", "question_id": "ABMS20260101_kimi-k2-thinking_p02-005", "question": "A 71-year-old man with history of scalp radiation for basal cell carcinoma 20 years ago develops a 5 cm recurrent tumor with 2 cm calvarial erosion. After oncologic resection, there is a full-thickness calvarial defect with dural exposure. What is the optimal reconstruction?", "options": ["A) Latissimus dorsi myocutaneous free flap with split-thickness skin graft", "B) Omental free flap with vascularized bone graft", "C) Pericranial flap rotation with split calvarial graft", "D) Latissimus dorsi muscle-only free flap with skin graft and delayed cranioplasty", "E) Anterolateral thigh fasciocutaneous flap with titanium mesh"], "answer": "D", "answer_index": 3, "explanation": "In irradiated scalp defects with calvarial exposure, muscle-only free flaps (latissimus dorsi) provide robust vascularity to compromised beds while allowing secondary skin grafting. The muscle conforms better to calvarial contours than fasciocutaneous flaps, and delayed cranioplasty after soft tissue healing reduces hardware exposure risk. Myocutaneous flaps are too bulky, and local pericranial flaps have unreliable vascularity in previously irradiated fields.", "generator_model": "kimi-k2-thinking", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Plastic Surgery", "abms_specialty": "Plastic Surgery", "abms_source": "target_topic", "source_label_raw": "Plastic Surgery", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed130", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed130-008", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed130.jsonl", "pred": "D", "model_outputs": "NOT FOR CLINICAL USE.\n\nThe patient has a full-thickness calvarial defect with exposed dura after oncologic resection. This is a complex reconstructive scenario, compounded by a history of scalp radiation, which can compromise tissue vascularity and healing. The goals of reconstruction are to protect the brain and dura, restore structural integrity, and provide durable coverage.\n\nLet's analyze the options:\n\n*   A. Latissimus dorsi myocutaneous free flap with split-thickness skin graft: This option provides vascularized soft tissue coverage. However, it does not address the bony defect, and a split-thickness skin graft over a muscle flap might not be the most durable or cosmetically ideal coverage for the calvarium long-term, especially given the absence of bone underneath.\n*   B. Omental free flap with vascularized bone graft: An omental flap is excellent for covering exposed dura, but it is very bulky and may not provide ideal contour. Vascularized bone grafts can reconstruct the bone defect but can be technically demanding, and their integration with bulky omentum for skull reconstruction is less common as a primary choice for moderate to large defects compared to other methods.\n*   C. Pericranial flap rotation with split calvarial graft: A pericranial flap is a good option for covering exposed dura, and a split calvarial graft could provide a thin layer of bone. However, this approach is typically best suited for smaller defects, and the viability of the pericranium and donor bone in a previously irradiated field might be compromised.\n*   D. Latissimus dorsi muscle-only free flap with skin graft and delayed cranioplasty: This is a well-established staged approach for large or complex full-thickness calvarial defects, especially in irradiated patients. The latissimus dorsi muscle provides robust, well-vascularized coverage for the exposed dura, promoting wound healing and preventing infection. A split-thickness skin graft covers the muscle. Delaying the cranioplasty (using autogenous bone or prosthetic material) allows the soft tissue flap to heal and become well-vascularized, significantly reducing the risk of infection and hardware extrusion associated with immediate rigid reconstruction in a compromised wound bed. This staged approach prioritizes safety and optimal conditions for definitive reconstruction.\n*   E. Anterolateral thigh fasciocutaneous flap with titanium mesh: An ALT flap provides good soft tissue coverage, and titanium mesh provides rigid structural reconstruction. However, placing a rigid implant like titanium mesh immediately on exposed dura in a radiated field carries a high risk of infection and subsequent complications. A staged approach is generally preferred.\n\nConsidering the combination of a full-thickness calvarial defect, dural exposure, and radiation history, a staged reconstruction that first ensures stable, well-vascularized soft tissue coverage, followed by definitive bony reconstruction, is considered optimal. Option D represents this best practice.\n\nThe answer is (D)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p02", "question_id": "ABMS20260101_kimi-k2-thinking_p02-006", "question": "A 28-year-old woman presents with progressive myelopathy over 6 months. MRI shows a holocord enhancing lesion from C2 to T9 with cystic components. Intraoperative neuromonitoring shows 60% amplitude reduction in motor evoked potentials after initial tumor debulking. What is the next surgical decision?", "options": ["A) Continue aggressive debulking despite signal changes", "B) Halt resection, perform duraplasty, and plan staged resection", "C) Switch to ultrasonic aspiration for gentler tumor removal", "D) Administer high-dose steroids and continue resection", "E) Perform en bloc resection of involved cord segments"], "answer": "B", "answer_index": 1, "explanation": "For holocord ependymoma, intraoperative neuromonitoring with >50% MEP amplitude reduction mandates immediate cessation of resection to prevent permanent neurologic deficit. Staged resection after allowing neural recovery (typically 3-6 months) achieves maximal safe cytoreduction. Continuing despite signal loss causes paraplegia, while en bloc resection is contraindicated in holocord lesions. Ultrasonic aspiration still transmits vibratory injury to compressed neural tissue.", "generator_model": "kimi-k2-thinking", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurological Surgery", "abms_specialty": "Neurological Surgery", "abms_source": "target_topic", "source_label_raw": "Neurological Surgery", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed130", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed130-009", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed130.jsonl", "pred": "B", "model_outputs": "NOT FOR CLINICAL USE.\nThe question describes a holocord lesion with cystic components causing progressive myelopathy. Crucially, intraoperative neuromonitoring (IOM) shows a 60% amplitude reduction in motor evoked potentials (MEPs) after initial debulking. This significant drop in MEP amplitude is a direct indicator of spinal cord compromise or impending damage.\n\nLet's analyze the options:\nA. Continuing aggressive debulking despite a 60% MEP reduction would be dangerous and likely result in severe or permanent neurological deficits. This option prioritizes tumor removal over spinal cord function.\nB. Halting resection is the most appropriate immediate step when significant neurological deterioration is detected by IOM. Performing duraplasty might be beneficial for CSF circulation or managing edema. Planning a staged resection is a conservative approach for extensive lesions, especially when neurological compromise has occurred, allowing for recovery and repeated assessment, thereby minimizing the risk of cumulative damage.\nC. Switching to ultrasonic aspiration is a change in technique. While potentially gentler, the problem highlighted by the MEP drop is the functional state of the cord, not necessarily the instrument used. If the cord is already compromised, further manipulation, even with a gentler tool, could be harmful.\nD. Administering high-dose steroids might help with potential edema, but it is not a substitute for stopping a procedure that is causing progressive neurological damage. Continuing resection after steroids would still carry a high risk.\nE. En bloc resection of involved cord segments implies removing significant portions of the spinal cord, which is only considered in specific contexts and is highly unlikely to be the safe choice given a holocord lesion and significant MEP reduction. This would almost certainly lead to severe functional loss.\n\nThe 60% amplitude reduction is a critical warning sign that necessitates stopping or significantly modifying the current surgical approach to protect neurological function. Option B directly addresses this by halting the procedure and planning a follow-up strategy.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p02", "question_id": "ABMS20260101_kimi-k2-thinking_p02-007", "question": "A 62-year-old man with T2N0M0 glottic carcinoma involving the anterior commissure is scheduled for definitive radiation therapy. He has good performance status and no comorbidities. What is the optimal fractionation scheme to maximize local control?", "options": ["A) 70 Gy in 35 fractions over 7 weeks with concurrent cisplatin", "B) 66 Gy in 33 fractions over 6.5 weeks with concurrent cetuximab", "C) 72 Gy in 42 fractions using concomitant boost over 6 weeks", "D) 60 Gy in 30 fractions over 6 weeks with hyperfractionation", "E) 50 Gy in 20 fractions over 4 weeks with hypofractionation"], "answer": "C", "answer_index": 2, "explanation": "For T2 glottic cancer with anterior commissure involvement, altered fractionation with concomitant boost (72 Gy/42 fractions/6 weeks) improves 5-year local control to 85% versus 70% with standard fractionation, without increasing late toxicity. The anterior commissure is a sanctuary site with poor vascularity, requiring higher biologically effective dose. Concurrent chemotherapy is not indicated for T2 disease and increases mucositis. Hypofractionation is reserved for early T1 lesions without commissure involvement.", "generator_model": "kimi-k2-thinking", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Radiation Oncology", "abms_specialty": "Radiation Oncology", "abms_source": "target_topic", "source_label_raw": "Radiation Oncology", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed130", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed130-020", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed130.jsonl", "pred": "C", "model_outputs": "The question asks for the optimal fractionation scheme to maximize local control for a 62-year-old man with T2N0M0 glottic carcinoma involving the anterior commissure, treated with definitive radiation therapy.\n\nLet's analyze the options:\nA.  70 Gy in 35 fractions over 7 weeks with concurrent cisplatin: This represents a standard, well-established fractionation and treatment regimen for locally advanced head and neck cancers. A dose of 70 Gy delivered in 2 Gy fractions over 7 weeks (5 fractions per week) is considered curative and provides good local control. Concurrent cisplatin is the standard chemotherapy in this setting.\n\nB.  66 Gy in 33 fractions over 6.5 weeks with concurrent cetuximab: While 66 Gy is within the therapeutic range, it's slightly lower than the typical 70 Gy or higher doses considered for maximizing control in challenging lesions. Cetuximab, while used in head and neck cancer, is not as universally established as cisplatin for concurrent chemoradiation in improving local control for this specific indication.\n\nC.  72 Gy in 42 fractions using concomitant boost over 6 weeks: This option proposes a higher total dose (72 Gy vs. 70 Gy) and a shorter overall treatment time (6 weeks vs. 7 weeks). Radiobiologically, higher doses and shorter treatment durations (through accelerated fractionation or hyperfractionation) are generally associated with improved local control, as they can overcome tumor cell repopulation and increase the biologically effective dose (BED). The description \"42 fractions over 6 weeks\" implies an average of 7 fractions per week. If this refers to a daily radiation therapy schedule (7 days a week) with fractions of 1.71 Gy (72 Gy / 42 fractions), this regimen would deliver a higher BED than conventional 2 Gy daily fractionation over 7 weeks. The term \"concomitant boost\" suggests techniques used to escalate dose to the primary tumor volume within the overall treatment. This combination of higher dose and accelerated overall time makes it a strong candidate for maximizing local control.\n\nD.  60 Gy in 30 fractions over 6 weeks with hyperfractionation: A total dose of 60 Gy is generally considered insufficient for curative-intent treatment of a T2 glottic carcinoma. Furthermore, the description \"with hyperfractionation\" is inconsistent with 30 fractions of 2 Gy, which is conventional fractionation.\n\nE.  50 Gy in 20 fractions over 4 weeks with hypofractionation: A total dose of 50 Gy is significantly too low for definitive curative radiation therapy for this stage and type of cancer. Hypofractionation (larger dose per fraction) at this dose would likely lead to substantial late toxicity without achieving adequate local control.\n\nComparing options A and C for *maximizing* local control: Option C proposes a higher cumulative dose and a shorter overall treatment time, coupled with a technique (\"concomitant boost\") designed to optimize dose delivery to the tumor. While Option A is a strong and proven standard, Option C represents an approach aimed at pushing the boundaries for local control through dose escalation and acceleration. Assuming the fractionation scheme in C is clinically feasible and well-tolerated to achieve 72 Gy in 6 weeks, it is radiobiologically expected to yield superior local control compared to the standard 70 Gy regimen.\n\nThe final answer is $\\boxed{C}$."}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p02", "question_id": "ABMS20260101_kimi-k2-thinking_p02-008", "question": "A 68-year-old man is 18 days post-Ivor Lewis esophagectomy with gastric conduit reconstruction for stage III esophageal adenocarcinoma. He develops sudden onset cough with swallowing, respiratory distress, and sepsis. Chest CT demonstrates a 5 mm fistula between the gastric conduit and right mainstem bronchus at the level of the carina, with surrounding mediastinal air and fluid. Bronchoscopy confirms the fistula with conduit mucosa visible. What is the definitive management?", "options": ["A) Endoscopic placement of overlapping esophageal and airway stents", "B) Emergency right thoracotomy with fistula repair using intercostal muscle flap and conduit resection with cervical esophagostomy", "C) NPO status, total parenteral nutrition, and broad-spectrum antibiotics for 6 weeks", "D) Bronchoscopic application of fibrin glue and continued enteral feeding via jejunostomy", "E) Cervical esophagostomy and conduit abandonment without fistula repair"], "answer": "B", "answer_index": 1, "explanation": "Early postoperative tracheobronchial-gastric conduit fistula requires urgent surgical repair with viable muscle flap reinforcement; conduit ischemia at the anastomotic line necessitates conduit resection and delayed reconstruction. Endoscopic stenting has >80% failure rate in this setting due to conduit tension and ongoing contamination.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Thoracic Surgery", "abms_specialty": "Thoracic Surgery", "abms_source": "target_topic", "source_label_raw": "Thoracic Surgery", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-001", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed131.jsonl", "pred": "B", "model_outputs": "The patient has developed a bronchogastric fistula 18 days after an Ivor Lewis esophagectomy, presenting with cough, respiratory distress, and sepsis. This is a severe complication requiring definitive management.\n\nLet's analyze the options:\nA. Endoscopic placement of overlapping esophageal and airway stents: While endoscopic interventions can sometimes be used to bridge fistulas or provide temporary palliation, they are generally not considered definitive management for a large, infected fistula causing sepsis, especially in the mediastinum. The risk of leakage and ongoing contamination remains high.\n\nB. Emergency right thoracotomy with fistula repair using intercostal muscle flap and conduit resection with cervical esophagostomy: This option describes a comprehensive surgical approach.\n    - Emergency right thoracotomy provides surgical access to the mediastinum.\n    - Fistula repair with an intercostal muscle flap is a standard technique for reinforcing repairs of difficult fistulas to prevent recurrence.\n    - Conduit resection addresses the possibly contaminated gastric conduit.\n    - Cervical esophagostomy creates a necessary diversion for the digestive tract above the resected segment.\nThis combination represents a definitive surgical solution for a complicated bronchogastric fistula.\n\nC. NPO status, total parenteral nutrition, and broad-spectrum antibiotics for 6 weeks: This is supportive care. While essential for managing sepsis and nutritional support, it does not address the anatomical defect of the fistula, which is the root cause. It is not definitive management.\n\nD. Bronchoscopic application of fibrin glue and continued enteral feeding via jejunostomy: Fibrin glue might be considered for small or recent fistulas, but for a potentially large fistula with mediastinal involvement and sepsis, it is unlikely to be sufficient for definitive closure. Continued enteral feeding via jejunostomy is part of nutritional management but not the definitive treatment for the fistula itself.\n\nE. Cervical esophagostomy and conduit abandonment without fistula repair: Diverting the gastrointestinal tract by bringing the esophagus to the neck (cervical esophagostomy) and abandoning the conduit (resection of the affected segment) are often parts of surgical management. However, this option explicitly states \"without fistula repair.\" If the fistula between the airway and the gastric conduit is not surgically closed or sealed, leakage may persist, leading to continued contamination and sepsis, making it less definitive than a direct repair. Option B includes direct repair.\n\nGiven the presence of sepsis and respiratory distress, definitive treatment aimed at sealing the fistula and controlling the source of infection is required. Option B offers the most complete and definitive surgical solution for this severe complication.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p02", "question_id": "ABMS20260101_kimi-k2-thinking_p02-009", "question": "A 72-year-old man has a 5.5 cm infrarenal abdominal aortic aneurysm with a thick circumferential rind of periaortic inflammation, bilateral ureteral obstruction with hydronephrosis, and elevated ESR (85 mm/hr) and CRP (120 mg/L). What is the optimal management sequence?", "options": ["A) Immediate open surgical repair with prednisone 1 mg/kg", "B) Endovascular aortic repair (EVAR) then prednisone 1 mg/kg", "C) Prednisone 40 mg daily for 6 weeks then open surgical repair", "D) Prednisone 40 mg daily for 6 weeks then EVAR", "E) Prednisone alone without aortic repair"], "answer": "D", "answer_index": 3, "explanation": "Inflammatory AAA requires initial steroid therapy to reduce periaortic inflammation and relieve ureteral obstruction. Delayed EVAR is preferred over open repair due to severe periaortic inflammation that increases surgical morbidity. Steroids alone risk aneurysm rupture.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Vascular Surgery", "abms_specialty": "Vascular Surgery", "abms_source": "target_topic", "source_label_raw": "Vascular Surgery", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-012", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed131.jsonl", "pred": "D", "model_outputs": "The patient presents with a large abdominal aortic aneurysm (AAA) complicated by significant periaortic inflammation, evidenced by the circumferential rind and elevated inflammatory markers (ESR and CRP). This is characteristic of an inflammatory AAA, which carries a higher risk of rupture and is technically more challenging to repair. Furthermore, the aneurysm is causing bilateral ureteral obstruction with hydronephrosis, a serious complication that can lead to renal failure.\n\nThe management of inflammatory AAA typically involves addressing the underlying inflammation prior to definitive repair. Corticosteroid therapy has been shown to reduce periaortic inflammation, decrease operative complications, and simplify surgical dissection in these cases.\n\nOptions A and B suggest immediate surgical repair (either open or endovascular) with concurrent or immediate post-operative steroid administration. However, operating while significant inflammation is present is associated with increased risks of bleeding, adherence to surrounding structures, and graft complications. Therefore, a staged approach, addressing inflammation first, is generally preferred.\n\nOption E, prednisone alone without aortic repair, is insufficient as it does not address the life-threatening risk of AAA rupture or the direct mass effect causing ureteral obstruction.\n\nOptions C and D propose treating the inflammation with prednisone (40 mg daily for 6 weeks, a standard regimen) followed by aortic repair. This staged approach is the cornerstone of managing inflammatory AAA. The decision then rests between open surgical repair (OSR) and endovascular aortic repair (EVAR).\n\nWhile both EVAR and OSR can be technically challenging in the setting of inflammatory AAA due to dense fibrosis and adhesions, EVAR is generally favored due to its lower invasiveness and reduced perioperative morbidity and mortality, particularly in older patients. Pre-treatment with steroids aims to reduce the severity of inflammation, potentially making the aneurysm neck more amenable to secure endograft sealing, and may also lead to some degree of ureteral decompression.\n\nTherefore, the optimal management sequence involves reducing the inflammation with corticosteroids first, followed by the less invasive EVAR if the anatomy is suitable.\n\nThe final answer is $\\boxed{D}$."}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p02", "question_id": "ABMS20260101_kimi-k2-thinking_p02-010", "question": "An 18-year-old male with genetically confirmed Danon disease (LAMP2 mutation) presents with severe hypertrophic cardiomyopathy (septal thickness 28 mm), ventricular pre-excitation (WPW pattern on ECG), and recurrent syncope. Electrophysiology study identifies three distinct accessory pathways. Despite maximal medical therapy, he continues to have pre-excited atrial fibrillation. What is the most appropriate next management step?", "options": ["A) Initiate flecainide therapy", "B) Perform catheter ablation of all accessory pathways", "C) Increase beta-blocker dosage", "D) Evaluate for heart transplantation", "E) Implant a dual-chamber pacemaker"], "answer": "D", "answer_index": 3, "explanation": "Danon disease causes rapidly progressive HCM, multiple accessory pathways, and skeletal myopathy with poor prognosis. Catheter ablation is often unsuccessful due to rapid pathway recurrence and progressive myocardial involvement. Beta-blockers and verapamil are contraindicated in WPW with pre-excited AF. Flecainide may transiently suppress pathways but doesn't alter disease course. Early heart transplant evaluation is recommended given the high mortality from arrhythmias and heart failure.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Cardiovascular", "abms_specialty": "Cardiovascular", "abms_source": "topics_mapped", "source_label_raw": "cardiology", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-003", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed124", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed124.jsonl", "pred": "B", "model_outputs": "NOT FOR CLINICAL USE.\nThe patient presents with confirmed Danon disease, severe hypertrophic cardiomyopathy, ventricular pre-excitation, and recurrent syncope due to pre-excited atrial fibrillation originating from three distinct accessory pathways. He has failed maximal medical therapy.\n\nLet's evaluate the options:\nA. Initiate flecainide therapy: Flecainide is an antiarrhythmic medication. While it can slow conduction, using it in patients with pre-excitation and atrial fibrillation can be dangerous. It might preferentially slow conduction down the AV node, leading to faster conduction down the accessory pathway, potentially causing a faster ventricular rate and increasing the risk of ventricular fibrillation. Given the presence of multiple accessory pathways and severe cardiomyopathy, this is not the safest or most effective next step.\n\nB. Perform catheter ablation of all accessory pathways: Catheter ablation is the definitive treatment for accessory pathway-mediated tachyarrhythmias, including symptomatic atrial fibrillation with rapid ventricular response. In this young patient with recurrent syncope and failure of medical therapy, eradicating the accessory pathways is the most appropriate and curative approach to prevent life-threatening arrhythmias and improve his quality of life.\n\nC. Increase beta-blocker dosage: Beta-blockers are often used for rate control in atrial fibrillation and may have some benefit in hypertrophic cardiomyopathy. However, the patient is already on maximal medical therapy, and the primary problem is the rapid conduction down accessory pathways. Beta-blockers do not eliminate the accessory pathways and are unlikely to resolve the recurrent symptomatic episodes when medication has already failed.\n\nD. Evaluate for heart transplantation: Heart transplantation is considered for patients with end-stage heart failure or severe, irreversible, and progressive cardiomyopathy. While Danon disease can lead to a progressive cardiomyopathy, the immediate life-threatening issue described is the recurrent, symptomatic pre-excited atrial fibrillation. Before considering transplantation, it is standard practice to address potentially curable causes of morbidity and mortality, such as symptomatic arrhythmias from accessory pathways. Ablation is the next logical step.\n\nE. Implant a dual-chamber pacemaker: A dual-chamber pacemaker is primarily indicated for symptomatic bradycardia or heart block. It does not address the presence of accessory pathways or the risk of rapid conduction through them during atrial fibrillation. Therefore, it is not an appropriate management strategy for this patient's condition.\n\nConsidering the patient's condition and the effectiveness of available treatments, catheter ablation of the accessory pathways is the most appropriate next management step to address the symptomatic, life-threatening arrhythmia refractory to medical therapy.\n\nThe answer is (B)"}]